AI Article Synopsis
- Neutralizing antibody titers are crucial for assessing how effective vaccinations (like Moderna and Pfizer) are against SARS-CoV-2.
- In a study involving vaccinated patients from Western New York, strong antibody levels were linked to effective neutralization of the Delta variant, but not the Omicron BA.5 subvariant.
- Ongoing research will explore how updated booster shots impact antibody responses and neutralization capabilities against emerging variants.
Article Abstract
Neutralizing antibody titers are an important measurement of the effectiveness of vaccination against SARS-CoV-2. Our laboratory has set out to further verify the functionality of these antibodies by measuring the neutralization capacity of patient samples against infectious SARS-CoV-2. Samples from patients from Western New York who had been vaccinated with the original Moderna and Pfizer vaccines (two doses) were tested for neutralization of both Delta (B.1.617.2) and Omicron (BA.5). Strong correlations between antibody levels and neutralization of the delta variant were attained; however, antibodies from the first two doses of the vaccines did not have good neutralization coverage of the subvariant omicron BA.5. Further studies are ongoing with local patient samples to determine correlation following updated booster administration.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057460 | PMC |
| http://dx.doi.org/10.3390/v15030793 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!